NO20004778L - Amidderivater og nociceptin antagonister - Google Patents

Amidderivater og nociceptin antagonister

Info

Publication number
NO20004778L
NO20004778L NO20004778A NO20004778A NO20004778L NO 20004778 L NO20004778 L NO 20004778L NO 20004778 A NO20004778 A NO 20004778A NO 20004778 A NO20004778 A NO 20004778A NO 20004778 L NO20004778 L NO 20004778L
Authority
NO
Norway
Prior art keywords
integer
compound
nociceptin
amide derivatives
hydroxy
Prior art date
Application number
NO20004778A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004778D0 (no
Inventor
Hisashi Shinkai
Takao Ito
Hideki Yamada
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO20004778D0 publication Critical patent/NO20004778D0/no
Publication of NO20004778L publication Critical patent/NO20004778L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
NO20004778A 1998-03-26 2000-09-25 Amidderivater og nociceptin antagonister NO20004778L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10002998 1998-03-26
PCT/JP1999/001462 WO1999048492A1 (fr) 1998-03-26 1999-03-23 Derives d'amide et antagonistes de nociceptine

Publications (2)

Publication Number Publication Date
NO20004778D0 NO20004778D0 (no) 2000-09-25
NO20004778L true NO20004778L (no) 2000-11-27

Family

ID=14263120

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004778A NO20004778L (no) 1998-03-26 2000-09-25 Amidderivater og nociceptin antagonister

Country Status (21)

Country Link
US (3) US6410561B1 (ja)
EP (1) EP1072263A4 (ja)
KR (1) KR20010042161A (ja)
CN (1) CN1301154A (ja)
AR (1) AR018168A1 (ja)
AU (1) AU754716B2 (ja)
BR (1) BR9909666A (ja)
CA (1) CA2325638A1 (ja)
CO (1) CO5080780A1 (ja)
FI (1) FI20002103A (ja)
HU (1) HUP0101275A3 (ja)
ID (1) ID26099A (ja)
IL (1) IL138573A0 (ja)
NO (1) NO20004778L (ja)
NZ (1) NZ507760A (ja)
RU (1) RU2202344C2 (ja)
SK (1) SK14272000A3 (ja)
TR (1) TR200003598T2 (ja)
TW (1) TW487571B (ja)
WO (1) WO1999048492A1 (ja)
ZA (1) ZA200005881B (ja)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3676100A (en) * 1999-04-09 2000-11-14 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
EP1537110B1 (en) 1999-12-06 2007-01-17 Euro-Celtique, S.A. Triazospiro compounds having nociceptin receptor affinity
JP4028730B2 (ja) 1999-12-06 2007-12-26 ユーロ−セルティーク エス．エイ． オピオイド受容体に対する親和性を有する３級アミノ化合物
JP2003524634A (ja) 1999-12-06 2003-08-19 ユーロ−セルティーク，エス．エイ． ノシセプチン受容体親和性を有するベンズイミダゾール化合物
DE19963175A1 (de) * 1999-12-27 2001-07-12 Gruenenthal Gmbh Verwendung von substituierten 4-Amino-1-phenylbutan-2-ol-Verbindungen als Arzneimittel
KR20020083533A (ko) 2000-03-31 2002-11-02 니뽄 신야쿠 가부시키가이샤 복소환 유도체 및 의약
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
NZ524421A (en) * 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
WO2002026714A1 (fr) * 2000-09-27 2002-04-04 Takeda Chemical Industries, Ltd. Composes spiraniques
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
SE0004054D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
CA2428787A1 (en) 2000-11-15 2002-05-23 Banyu Pharmaceutical Co., Ltd. Benzimidazole derivatives
AU2002218535A8 (en) * 2000-12-12 2008-01-17 Japan Tobacco Inc Pharmaceutical composition containing an active with a hemolytic action and a surfactant
WO2002074341A1 (fr) * 2001-03-19 2002-09-26 Nippon Shinyaku Co., Ltd. Antiprurigineux
KR100722207B1 (ko) 2001-04-18 2007-05-29 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
SI1975164T1 (sl) 2001-04-18 2010-05-31 Euro Celtique Sa Oktahidrobenzimidazolonske spojine kot analgetiki
CA2443938C (en) 2001-04-18 2010-06-22 R. Richard Goehring Spiroindene and spiroindane compounds as opioid ligands useful for treating pain
DK1598339T3 (da) 2001-04-18 2009-09-28 Euro Celtique Sa 1-(4-amino-cyclohexyl)-1,3-dihydro-2H-benzimidazol-2-on derivater og beslægtede forbindelser som nociceptin analoger og ORL1-ligander til behandling af smerte
BR0209127A (pt) 2001-04-18 2006-03-21 Euro Celtique Sa compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
AU2002343489A1 (en) 2001-10-09 2003-04-22 Synvax, Inc. Nociceptin-based analgesics
JP2005519876A (ja) * 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
US7566728B2 (en) * 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
US7235558B2 (en) * 2002-06-06 2007-06-26 Sanofi-Aventis Deutschland Gmbh Inhibitors of the GPIb—vWF interaction, their preparation and use
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1388342A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US7696225B2 (en) * 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
TWI299664B (en) * 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
WO2004103992A1 (ja) 2003-05-21 2004-12-02 Banyu Pharmaceutical Co., Ltd. ２－アミノキノリン誘導体
EP1669348A4 (en) 2003-09-30 2009-03-11 Eisai R&D Man Co Ltd NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND
TW200526631A (en) 2003-10-07 2005-08-16 Renovis Inc Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US20050084835A1 (en) * 2003-10-16 2005-04-21 The Singing Machine Company, Inc. Karaoke system with built-in camera
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP1568698A1 (en) * 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
ATE475640T1 (de) * 2004-03-12 2010-08-15 Lilly Co Eli Antagonisten des opioidrezeptors
JP5081448B2 (ja) 2004-06-09 2012-11-28 株式会社カネカ 硬化性組成物
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
WO2007085357A1 (en) 2006-01-30 2007-08-02 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
WO2008023333A2 (en) * 2006-08-22 2008-02-28 Ranbaxy Laboratories Limited Process for the preparation of 4-(isobutylamino)-3-amino-quinoline
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
AU2009236290A1 (en) * 2008-04-15 2009-10-22 Merck Sharp & Dohme Corp. Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and HPMCAS
CN103450206A (zh) 2008-07-30 2013-12-18 普渡制药公司 丁丙诺啡类似物
EA021437B1 (ru) 2009-09-29 2015-06-30 Глэксо Груп Лимитед Соединения, ингибирующие lrrk2 киназную активность
JP5855095B2 (ja) 2010-06-07 2016-02-09 ノボメディックス，エルエルシーＮｏｖｏｍｅｄｉｘ，Ｌｌｃ フラニル化合物およびその使用
TW201209037A (en) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
PE20140020A1 (es) 2010-09-21 2014-01-31 Purdue Pharma Lp Analogos de buprenorfina
US9458161B1 (en) 2011-11-03 2016-10-04 Vanderblit University TSPO ligands for cancer imaging and treatment
WO2013084060A1 (en) 2011-12-08 2013-06-13 Purdue Pharma L.P. Quaternized buprenorphine analogs
ES2649410T3 (es) 2011-12-21 2018-01-11 Novira Therapeutics Inc. Agentes antivirales para la hepatitis B
TW201408645A (zh) 2012-05-11 2014-03-01 Purdue Pharma Lp 苯並嗎凡類似物及其用途
TW201920090A (zh) 2012-08-28 2019-06-01 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基－芳醯胺類及其做為治療ｂ型肝炎之醫藥劑的用途
CA2890655A1 (en) 2012-11-09 2014-05-15 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
WO2014161888A1 (en) 2013-04-03 2014-10-09 Janssen R&D Ireland N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
AU2014294997B2 (en) 2013-07-25 2018-03-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
MX2016009449A (es) 2014-02-05 2016-10-13 Novira Therapeutics Inc Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb).
KR20160110419A (ko) 2014-02-06 2016-09-21 얀센 사이언시즈 아일랜드 유씨 술파모일피롤아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
JP6537532B2 (ja) 2014-02-25 2019-07-03 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体媒介障害の治療のための化合物
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
EP3139921A4 (en) 2014-05-06 2018-02-14 Purdue Pharma L.P. Benzomorphan analogs and use thereof
WO2016003886A1 (en) * 2014-07-02 2016-01-07 Lam Therapeutics, Inc. 4-aminoquinoline compositions and methods for using same
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
AR106018A1 (es) * 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
JP6845231B2 (ja) 2015-09-29 2021-03-17 ノヴィラ・セラピューティクス・インコーポレイテッド Ｂ型肝炎抗ウイルス薬の結晶形態
CN105461623A (zh) * 2015-12-29 2016-04-06 江苏理工学院 4-氨基-6-硝基-3-溴喹啉合成方法
CA3021068A1 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
CA3029262A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
ES2933513T3 (es) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Compuestos macrocíclicos para el tratamiento de trastornos médicos
EP3589628A4 (en) 2017-03-01 2021-03-31 Achillion Pharmaceuticals, Inc. ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISEASES
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
DE102017212649A1 (de) * 2017-07-24 2019-01-24 Beiersdorf Ag Verwendung von N-(4-amino-2-methylchinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamid zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auswirkungen ultravioletter Strahlung auf die Haut
BR112020018601A2 (pt) 2018-03-14 2020-12-29 Janssen Sciences Ireland Unlimited Company Regime de dosagem de modulador de montagem de capsídeo
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D
AU2019336238A1 (en) 2018-09-06 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of Complement factor D inhibitors
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
TW202045499A (zh) 2019-02-22 2020-12-16 愛爾蘭商健生科學愛爾蘭無限公司 用於治療ｈｂｖ感染或ｈｂｖ誘發疾病之醯胺衍生物
CN113795486A (zh) 2019-05-06 2021-12-14 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物
EP4003961A2 (en) * 2019-07-25 2022-06-01 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE590239C (de) * 1931-08-19 1933-12-28 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von quaternaeren Abkoemmlingen heterocyclischer Stickstoffverbindungen
DE947552C (de) * 1944-04-18 1956-09-06 Hoechst Ag Verfahren zur Herstellung von 4-Aminochinaldinverbindungen
GB1185539A (en) * 1967-11-03 1970-03-25 Smith & Nephew Substituted Tetrazoles
IE47458B1 (en) 1977-11-07 1984-03-21 Leo Pharm Prod Ltd Quinolylguanidine derivatives
IT1205640B (it) 1983-04-06 1989-03-23 Yason Srl Nuovi composti ad attivita' antiinfiammatoria,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
BR8606663A (pt) 1985-05-07 1987-08-11 Alkaloida Vegyeszeti Gyar Derivados de triazolil-quinolina
CA1306260C (en) 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
JPH07620B2 (ja) 1985-10-18 1995-01-11 塩野義製薬株式会社 縮合イミダゾピリジン誘導体
US4791112A (en) 1987-02-02 1988-12-13 The Boc Group, Inc. N-heterocyclic-N-(4-piperidyl)amides and pharmaceutical compositions and methods employing such compounds
US5019574A (en) 1988-09-30 1991-05-28 Chugai Seiyaku Kabushiki Kaisha 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function
JPH02167265A (ja) 1988-09-30 1990-06-27 Chugai Pharmaceut Co Ltd 新規な３，４―ジアミノキノリン及びピリジン系化合物
ES2095855T3 (es) * 1989-02-02 1997-03-01 Yamanouchi Pharma Co Ltd Derivados de tetrahidrobencimidazol.
AU638840B2 (en) * 1990-07-05 1993-07-08 Sumitomo Chemical Company, Limited Pyrimidine derivative
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
JP3697486B2 (ja) 1994-10-27 2005-09-21 アステラス製薬株式会社 ブラジキニン拮抗剤としての、ピリドピリミドン類、キノリン類および縮合ｎ−複素環類
DE69633196D1 (de) 1995-10-16 2004-09-23 Fujisawa Pharmaceutical Co Heterocyclische verbindungen als h+-atpasen

Also Published As

Publication number Publication date
TR200003598T2 (tr) 2001-06-21
WO1999048492A1 (fr) 1999-09-30
AU754716B2 (en) 2002-11-21
NZ507760A (en) 2002-10-25
US20060030565A1 (en) 2006-02-09
CO5080780A1 (es) 2001-09-25
RU2202344C2 (ru) 2003-04-20
US6903094B2 (en) 2005-06-07
NO20004778D0 (no) 2000-09-25
HUP0101275A3 (en) 2002-12-28
EP1072263A1 (en) 2001-01-31
EP1072263A4 (en) 2004-03-31
ID26099A (id) 2000-11-23
KR20010042161A (ko) 2001-05-25
CN1301154A (zh) 2001-06-27
ZA200005881B (en) 2001-08-23
US20030055087A1 (en) 2003-03-20
HUP0101275A2 (hu) 2001-09-28
US6410561B1 (en) 2002-06-25
AU2855899A (en) 1999-10-18
BR9909666A (pt) 2001-09-11
TW487571B (en) 2002-05-21
IL138573A0 (en) 2001-10-31
AR018168A1 (es) 2001-10-31
CA2325638A1 (en) 1999-09-30
FI20002103A (fi) 2000-11-17
SK14272000A3 (sk) 2001-05-10

Similar Documents

Publication Publication Date Title
NO20004778L (no) Amidderivater og nociceptin antagonister
UA72917C2 (en) Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
HUP0300444A2 (hu) Kálciumblokkolót tartalmazó stabilizált gyógyszerkészítmények
HUP0204283A2 (hu) (Kinolil-propil)-piperidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
TR200400185T4 (tr) PDE 5 inhibitörleri olarak, 8-kuinolinkisantin ve 8-izokuinolinkisantin türevleri.
BR0111596A (pt) Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças
HUP0302337A2 (hu) Pirimidin-2,4,6-trion metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PL322419A1 (en) Novel substituted compounds of biphenyl or phenylopyridine, method of obtaining them as well as pharmaceutic compositions containing such compounds
HUP0400467A2 (hu) 2-Iminopirrolidin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
FR2842804B1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
BR0015821A (pt) Derivados de pirimidina
HUP9802363A1 (hu) Herbicid hatású szulfonamidokszármazékok, a vegyületeket hatóanyagként tartalmazó herbicid készítmények és alkalmazásuk
HUP0102277A2 (hu) 3-Helyzetben heterociklusos csoporttal szubsztituált benzoesavszármazékot tartalmazó herbicid készítmény előállítása és alkalmazása
ES2105286T3 (es) Derivados de etanolamina que tienen actividades simpatomimetica y anti-polaquiuria.
HUP0004851A2 (hu) A motilinreceptor antagonistáiként alkalmazható új ciklopenténszérmazékok, ilyen származékokat tartalmazó gyógyszerkészítmények és eljárás a motilinreceptorral összefüggő rendellenességek kezelésére
RS50879B (sr) Kristalna natrijumova so telmisartana i njena primena kao angiotenzinskog antagonista
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
NO20055997L (no) Diarylmetylidenpiperidinderivater og deres anvendelse som opiodreseptoragonister
TR199900096T2 (xx) Bradykinin B2 antagonistleri olarak elveri�li N-benzensulfonil-L-prolin t�revleri.
DE69625913D1 (de) Inhibitor des erwerbs der abhängigkeit/resistenz gegen betäaubende analgetika
AU5125798A (en) Novel n-benzenesulphonyl-l-proline derivatives, method for preparing and therapeutic use
HUP0204516A2 (en) Synergistic fungicidal composition and its use
MY139258A (en) Carbamoyl-type benzofuran derivatives